EcoDrugPlus

5-Hydroxytryptamine Receptor 3b-Like

Ensembl ID : ENSCMIG00000000173
Gene Symbol: LOC103172212
2 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCMIG00000001765
Gene Symbol: HTR4
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a-Like

Ensembl ID : ENSCMIG00000006853
Gene Symbol: LOC103190269
4 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCMIG00000018875
Gene Symbol: HTR7
1 Cross references
220 Possible Orthologues:

60s Ribosomal Protein L17

Ensembl ID : ENSCMIG00000013948
Gene Symbol: LOC103187344
4 Cross references
715 Possible Orthologues:

60s Ribosomal Protein L5-Like

Ensembl ID : ENSCMIG00000006569
Gene Symbol: LOC103171726
3 Cross references
537 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCMIG00000016173
Gene Symbol: ABL1
4 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCMIG00000009330
Gene Symbol: ADAM17
4 Cross references
283 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCMIG00000017456
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCMIG00000015166
Gene Symbol: ADRM1
1 Cross references
262 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCMIG00000013261
Gene Symbol: AKT1
4 Cross references
221 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCMIG00000002011
Gene Symbol: ALK
1 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).